Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.

Axel De GreefRomane ThirionPierre-Dominique GhislainMarie Baeck

Published in: Dermatology and therapy (2023)

Baricitinib is effective in treating patients with alopecia areata, particularly for the patchy phenotype, but with a risk of relapse after discontinuation. Safety data are reassuring, with lipid changes being the most frequent adverse event.

Keyphrases

electronic health record
big data
randomized controlled trial
systematic review
early onset
data analysis
combination therapy
free survival
artificial intelligence
adverse drug
replacement therapy